A study to investigate the impact of dose and dosing frequency of AZD8848 on the response on biomarkers

Study identifier:D0540C00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2010-022574-14

CTIS identifier:N/A

Study Complete

Official Title

A single-blind, randomized, placebo controlled, parallel-group, adaptive-design study to investigate the impact of dose and dosing frequency of AZD8848 administered intranasally for up to 7 days, on the biomarker

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8848, Placebo

Sex

All

Actual Enrollment

55

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Feb 2012

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Aug 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria